FBT Fact Sheet: First Trust NYSE Arca Biotechnology Index Fund
Share
$257.00
close, Nov 20, 2026
Over the year to Nov 19, 2026, FBT returned +30.6% in total and charged 0.55% a year.
- 1-year total return
- +27.3%
- to Nov 20, 2026
- Expense ratio
- 0.55%
- a year
- Net assets
- $2.9bn
- on Nov 19, 2026
- Net flow, last 5 trading days
- −$53.2m
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
FBT $13,065 +30.6% · IVV $10,925 +9.2% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−5.7%
3 months−5.1%
Year to date+24.4%
1 year+27.3%
3 years+85.6%
5 years+64.6%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Genmab A/S (ADR)4.67%
ADMA Biologics, Inc.4.34%
Regeneron Pharmaceuticals, Inc.4.17%
TG Therapeutics, Inc.3.95%
argenx SE (ADR)3.85%
Alkermes Plc3.83%
BeOne Medicines Ltd. (ADR)3.80%
BioMarin Pharmaceutical Inc.3.78%
Exelixis, Inc.3.71%
Gilead Sciences, Inc.3.71%
FBT top ten by weight, 39.8% of the fund, of its 30 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 30 stocks in biotech, 25% of its weight in S&P 500 companies · First traded Jun 23, 2006 · Benchmark Its own holdings, as of Nov 19, 2026